A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.9070-9073
Hauptverfasser:	Zeidner, Joshua F., Foster, Matthew C., Johnson, Mary, Huang, Ying, Swords, Ronan T., Stein, Eytan, Foran, James M., Baer, Maria R., Stock, Wendy, Madanat, Yazan F., Kovacsovics, Tibor, Olin, Rebecca L., Blum, William G., Schiller, Gary J., Lin, Tara L., Redner, Robert L., Al-Mansour, Zeina, Curran, Emily K, Heerema, Nyla A., Martycz, Molly, Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O., Chen, Timothy, Stefanos, Mona, Druggan, Franchesca, Burd, Amy, Levine, Ross L., Druker, Brian J., Borate, Uma, Byrd, John C., Mims, Alice S.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!